Broad spectrum of interferon-related nephropathies-glomerulonephritis, systemic lupus erythematosus-like syndrome and thrombotic microangiopathy: A case report and review of literature.
Eculizumab
Interferon
Nephrotoxicity
Systemic lupus erythematosus
Thrombotic microangiopathy
Journal
World journal of nephrology
ISSN: 2220-6124
Titre abrégé: World J Nephrol
Pays: United States
ID NLM: 101610229
Informations de publication
Date de publication:
12 Nov 2019
12 Nov 2019
Historique:
received:
06
06
2019
revised:
04
09
2019
accepted:
22
09
2019
entrez:
22
11
2019
pubmed:
22
11
2019
medline:
22
11
2019
Statut:
ppublish
Résumé
Interferons (IFNs) are characterized by a wide range of biological effects, which justifies their potential therapeutic use in several pathologies, but also elicit a wide array of adverse effects in almost every organ system. Among them, renal involvement is probably one of the most complex to identify. We describe four cases of kidney damage caused by different IFN formulations: IFN-β-related thrombotic microangiopathy, IFN-β-induced systemic lupus erythematosus, and two cases of membranous nephropathy secondary to pegylated-IFN-α 2B. In each case, we carefully excluded any other possible cause of renal involvement. Once suspected as the casual relationship between drug and kidney damage, IFN treatment was immediately discontinued. In three cases, we observed a complete and persistent remission of clinical and laboratory abnormalities after IFN withdrawal, while the patient who developed thrombotic microangiopathy, despite IFN withdrawal and complement-inhibitor therapy with eculizumab, showed persistent severe renal failure requiring dialysis. This case series highlights the causal relationship between IFN treatment and different types of renal involvement and enables us to delineate several peculiarities of this association.
Sections du résumé
BACKGROUND
BACKGROUND
Interferons (IFNs) are characterized by a wide range of biological effects, which justifies their potential therapeutic use in several pathologies, but also elicit a wide array of adverse effects in almost every organ system. Among them, renal involvement is probably one of the most complex to identify.
CASE SUMMARY
METHODS
We describe four cases of kidney damage caused by different IFN formulations: IFN-β-related thrombotic microangiopathy, IFN-β-induced systemic lupus erythematosus, and two cases of membranous nephropathy secondary to pegylated-IFN-α 2B. In each case, we carefully excluded any other possible cause of renal involvement. Once suspected as the casual relationship between drug and kidney damage, IFN treatment was immediately discontinued. In three cases, we observed a complete and persistent remission of clinical and laboratory abnormalities after IFN withdrawal, while the patient who developed thrombotic microangiopathy, despite IFN withdrawal and complement-inhibitor therapy with eculizumab, showed persistent severe renal failure requiring dialysis.
CONCLUSION
CONCLUSIONS
This case series highlights the causal relationship between IFN treatment and different types of renal involvement and enables us to delineate several peculiarities of this association.
Identifiants
pubmed: 31750091
doi: 10.5527/wjn.v8.i7.109
pmc: PMC6853798
doi:
Types de publication
Case Reports
Langues
eng
Pagination
109-117Informations de copyright
©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflict-of-interest statement: The authors have no conflicts of interest to declare.
Références
Nephrol Dial Transplant. 2004 Aug;19(8):2155
pubmed: 15252182
Nephron. 1998 Sep;80(1):107-8
pubmed: 9730725
Clin J Am Soc Nephrol. 2015 Jul 7;10(7):1291-9
pubmed: 25862776
Autoimmun Rev. 2018 Sep;17(9):912-918
pubmed: 30005854
Kidney Int. 2013 Nov;84(5):874-9
pubmed: 23823603
Nephrol Dial Transplant. 1995;10(8):1441-3
pubmed: 8538940
Am J Pathol. 2013 Aug;183(2):431-40
pubmed: 23747509
Clin Nephrol. 2012 Jun;77(6):496-500
pubmed: 22595393
Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2610-5
pubmed: 12604793
J Invest Dermatol. 1990 Dec;95(6 Suppl):66S-71S
pubmed: 1701811
Blood. 2016 Dec 15;128(24):2824-2833
pubmed: 27663672
Cancer. 1990 May 15;65(10):2237-42
pubmed: 2346907
South Med J. 1996 Aug;89(8):810-4
pubmed: 8701383
Thromb Res. 2018 Mar;163:105-116
pubmed: 29407621
N Engl J Med. 2014 Mar 27;370(13):1270-1
pubmed: 24670186
Clin Kidney J. 2017 Oct;10(5):625-631
pubmed: 28980667
J Gastroenterol. 2002;37(10):854-8
pubmed: 12424571
Crit Rev Oncol Hematol. 2017 Apr;112:103-112
pubmed: 28325251
J Rheumatol. 1991 Oct;18(10):1621-2
pubmed: 1765991
J Interferon Cytokine Res. 2003 Jan;23(1):51-4
pubmed: 12639299
Adv Ther. 2015 May;32(5):445-54
pubmed: 25991578
J Immunol. 2014 Jun 15;192(12):5459-68
pubmed: 24907379
Can J Neurol Sci. 2005 Aug;32(3):366-8
pubmed: 16225183
Am J Hematol. 2015 May;90(5):406-10
pubmed: 25639727
Autoimmun Rev. 2015 Aug;14(8):692-702
pubmed: 25888464
J Clin Oncol. 1986 Feb;4(2):234-43
pubmed: 2418169
Kidney Int. 2010 May;77(10):848-54
pubmed: 20237459
Clin J Am Soc Nephrol. 2010 Apr;5(4):607-15
pubmed: 20203164
Ren Fail. 1991;13(2-3):87-93
pubmed: 1957045
Mult Scler Relat Disord. 2014 May;3(3):321-5
pubmed: 25876469
Ann N Y Acad Sci. 2007 Jun;1108:166-82
pubmed: 17893983
Kidney Int. 2014 Jan;85(1):213-4
pubmed: 24380910
Clin Liver Dis. 2017 Aug;21(3):487-497
pubmed: 28689588
Rev Med Interne. 1995;16(9):691-5
pubmed: 7481158
Am J Kidney Dis. 1994 Nov;24(5):858-63
pubmed: 7977330
Am J Clin Oncol. 2003 Jun;26(3):262-4
pubmed: 12796597
Intern Med J. 2019 Feb;49(2):274-276
pubmed: 30754081
Ren Fail. 1993;15(4):559-61
pubmed: 8210571
Clin Rheumatol. 1999;18(2):177-9
pubmed: 10357129
Acta Haematol. 2002;107(3):133-44
pubmed: 11978934
Am J Kidney Dis. 1996 Dec;28(6):888-92
pubmed: 8957041
Medicine (Baltimore). 2002 Jul;81(4):321-31
pubmed: 12169887
J Neurol. 2013 Jul;260(7):1915-6
pubmed: 23708674
Am J Kidney Dis. 1999 Jun;33(6):1040-8
pubmed: 10352191
Arthritis Res Ther. 2010;12(5):219
pubmed: 21062511
Am J Hematol. 1995 Aug;49(4):355-6
pubmed: 7639284